Cargando…

Preclinical pharmacokinetics, biodistribution, radiation dosimetry and toxicity studies required for regulatory approval of a phase I clinical trial with (111)In-CP04 in medullary thyroid carcinoma patients

INTRODUCTION: From a series of radiolabelled cholecystokinin (CCK) and gastrin analogues, (111)In-CP04 ((111)In-DOTA-(DGlu)(6)-Ala-Tyr-Gly-Trp-Met-Asp-Phe-NH(2)) was selected for further translation as a diagnostic radiopharmaceutical towards a first-in-man study in patients with medullary thyroid c...

Descripción completa

Detalles Bibliográficos
Autores principales:	Maina, Theodosia, Konijnenberg, Mark W., KolencPeitl, Petra, Garnuszek, Piotr, Nock, Berthold A., Kaloudi, Aikaterini, Kroselj, Marko, Zaletel, Katja, Maecke, Helmut, Mansi, Rosalba, Erba, Paola, von Guggenberg, Elisabeth, Hubalewska-Dydejczyk, Alicja, Mikolajczak, Renata, Decristoforo, Clemens
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	2016
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4948680/ https://www.ncbi.nlm.nih.gov/pubmed/27185299 http://dx.doi.org/10.1016/j.ejps.2016.05.011

Ejemplares similares

From preclinical development to clinical application: Kit formulation for radiolabelling the minigastrin analogue CP04 with In-111 for a first-in-human clinical trial
por: Pawlak, Dariusz, et al.
Publicado: (2016)

Clinical translation of theranostic radiopharmaceuticals: Current regulatory status and recent examples
por: Kolenc Peitl, Petra, et al.
Publicado: (2019)

A novel CCK(2)/gastrin receptor-localizing radiolabeled peptide probe for personalized diagnosis and therapy of patients with progressive or metastatic medullary thyroid carcinoma: a multicenter phase I GRAN-T-MTC study
por: Erba, Paola A., et al.
Publicado: (2018)

[(111)In]In-CP04 as a novel cholecystokinin-2 receptor ligand with theranostic potential in patients with progressive or metastatic medullary thyroid cancer: final results of a GRAN-T-MTC Phase I clinical trial
por: Lezaic, Luka, et al.
Publicado: (2022)

Selection of the First (99m)Tc-Labelled Somatostatin Receptor Subtype 2 Antagonist for Clinical Translation—Preclinical Assessment of Two Optimized Candidates
por: Fani, Melpomeni, et al.
Publicado: (2020)

Development of the (99m)Tc-Labelled SST(2) Antagonist TECANT-1 for a First-in-Man Multicentre Clinical Study
por: Novak, Doroteja, et al.
Publicado: (2023)

Update on Preclinical Development and Clinical Translation of Cholecystokinin-2 Receptor Targeting Radiopharmaceuticals
por: von Guggenberg, Elisabeth, et al.
Publicado: (2021)

Comparative biodistribution of 12 (111)In-labelled gastrin/CCK2 receptor-targeting peptides
por: Laverman, Peter, et al.
Publicado: (2011)

Comparison of 99mTc radiolabeled somatostatin antagonist with [(68) Ga]Ga-DOTA-TATE in a patient with advanced neuroendocrine tumor
por: Opalinska, Marta, et al.
Publicado: (2023)

Comparing Gly(11)/dAla(11)-Replacement vs. the in-Situ Neprilysin-Inhibition Approach on the Tumor-targeting Efficacy of the (111)In-SB3/(111)In-SB4 Radiotracer Pair
por: Lymperis, Emmanouil, et al.
Publicado: (2019)

Impact of clinically tested NEP/ACE inhibitors on tumor uptake of [(111)In-DOTA]MG11—first estimates for clinical translation
por: Kaloudi, Aikaterini, et al.
Publicado: (2016)

[(99m)Tc]Tc-DB15 in GRPR-Targeted Tumor Imaging with SPECT: From Preclinical Evaluation to the First Clinical Outcomes
por: Nock, Berthold A., et al.
Publicado: (2021)

Peptide Radioligands in Cancer Theranostics: Agonists and Antagonists
por: Nock, Berthold A., et al.
Publicado: (2023)

One Step Closer to Clinical Translation: Enhanced Tumor Targeting of [(99m)Tc]Tc-DB4 and [(111)In]In-SG4 in Mice Treated with Entresto
por: Kanellopoulos, Panagiotis, et al.
Publicado: (2020)

Key-Protease Inhibition Regimens Promote Tumor Targeting of Neurotensin Radioligands
por: Kanellopoulos, Panagiotis, et al.
Publicado: (2020)

Influence of DOTA Chelators on Radiochemical Purity and Biodistribution of (177)Lu- and (90)Y-Rituximab in Xenografted Mice
por: Karczmarczyk, Urszula, et al.
Publicado: (2018)

Modifier Role of Common RET Variants in Sporadic Medullary Thyroid Carcinoma
por: Skalniak, Anna, et al.
Publicado: (2021)

[(99m)Tc]Tc-DB1 Mimics with Different-Length PEG Spacers: Preclinical Comparison in GRPR-Positive Models
por: Kanellopoulos, Panagiotis, et al.
Publicado: (2020)

Radiolabeled Bombesin Analogs
por: Mansi, Rosalba, et al.
Publicado: (2021)

PSAT384 Familial Non-Medullary Thyroid Cancer — Does The Number Of Alanine Residues In The FOXE1 Gene Play A Role?
por: Trofimiuk-Muldner, Malgorzata, et al.
Publicado: (2022)

Targeting prostate cancer with radiolabelled bombesins
por: Maina, Theodosia, et al.
Publicado: (2006)

NeoBOMB1, a GRPR-Antagonist for Breast Cancer Theragnostics: First Results of a Preclinical Study with [(67)Ga]NeoBOMB1 in T-47D Cells and Tumor-Bearing Mice
por: Kaloudi, Aikaterini, et al.
Publicado: (2017)

Localization of (99m)Tc-GRP Analogs in GRPR-Expressing Tumors: Effects of Peptide Length and Neprilysin Inhibition on Biological Responses
por: Kaloudi, Aikaterini, et al.
Publicado: (2019)

Glucagon-Like Peptide-1 Receptor Imaging with [Lys(40)(Ahx-HYNIC-(99m)Tc/EDDA)NH(2)]-Exendin-4 for the Diagnosis of Recurrence or Dissemination of Medullary Thyroid Cancer: A Preliminary Report
por: Pach, D., et al.
Publicado: (2013)

Improved quality control of [(177)Lu]Lu-PSMA I&T
por: Kraihammer, Martin, et al.
Publicado: (2023)

Design and Evaluation of (223)Ra-Labeled and Anti-PSMA Targeted NaA Nanozeolites for Prostate Cancer Therapy—Part II. Toxicity, Pharmacokinetics and Biodistribution
por: Lankoff, Anna, et al.
Publicado: (2021)

Imaging of inflamed carotid artery atherosclerotic plaques with the use of (99m)Tc-HYNIC-IL-2 scintigraphy in end-stage renal disease patients
por: Opalinska, Marta, et al.
Publicado: (2012)

Position paper on requirements for toxicological studies in the specific case of radiopharmaceuticals
por: Koziorowski, J., et al.
Publicado: (2016)

Clinical results of radionuclide therapy of neuroendocrine tumours with (90)Y-DOTATATE and tandem (90)Y/(177)Lu-DOTATATE: which is a better therapy option?
por: Kunikowska, Jolanta, et al.
Publicado: (2011)

How far are we from understanding the genetic basis of Hashimoto’s thyroiditis?
por: Hubalewska-Dydejczyk, Alicja
Publicado: (2013)

Comparison of three radiolabelled peptide analogues for CCK-2 receptor scintigraphy in medullary thyroid carcinoma
por: Fröberg, Alida C., et al.
Publicado: (2009)

Optimizing the Profile of [(99m)Tc]Tc–NT(7–13) Tracers in Pancreatic Cancer Models by Means of Protease Inhibitors
por: Kanellopoulos, Panagiotis, et al.
Publicado: (2020)

Toward Stability Enhancement of NTS(1)R-Targeted Radioligands: Structural Interventions on [(99m)Tc]Tc-DT1
por: Kanellopoulos, Panagiotis, et al.
Publicado: (2023)

Current Status of Radiopharmaceuticals for the Theranostics of Neuroendocrine Neoplasms
por: Fani, Melpomeni, et al.
Publicado: (2017)

FRI111 Venous Thromboembolism In Cushing Syndrome - A Call For Standardized Anticoagulation Regimen In Hypercortisolism
por: Minasyan, Mari, et al.
Publicado: (2023)

[(111)In-DOTA]Somatostatin-14 analogs as potential pansomatostatin-like radiotracers - first results of a preclinical study
por: Tatsi, Aikaterini, et al.
Publicado: (2012)

Trastuzumab cotreatment improves survival of mice with PC‐3 prostate cancer xenografts treated with the GRPR antagonist (177)Lu‐DOTAGA‐PEG(2)‐RM26
por: Mitran, Bogdan, et al.
Publicado: (2019)

The development of guidelines for management of thyroid diseases in pregnancy – current status
por: Hubalewska-Dydejczyk, Alicja, et al.
Publicado: (2015)

[(68)Ga]Ga-DATA(5m)-LM4, a PET Radiotracer in the Diagnosis of SST(2)R-Positive Tumors: Preclinical and First Clinical Results
por: Kanellopoulos, Panagiotis, et al.
Publicado: (2022)

Side-Chain Modified [(99m)Tc]Tc-DT1 Mimics: A Comparative Study in NTS(1)R-Positive Models
por: Kanellopoulos, Panagiotis, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_007rbmmqd6u8nenmn9hul0j19m